Navigation Links
Warner Chilcott Announces FDA Approval of Next Generation Actonel
Date:10/11/2010

nopausal osteoporosis in the United States.  The product will be marketed as ATELVIA™ (risedronate sodium) delayed-release tablets.  

"The approval of ATELVIA represents an exciting addition to the ACTONEL franchise, as well as our women's healthcare product portfolio.  We believe the dosing convenience of ATELVIA sets it apart from other treatment options for osteoporosis patients and provides an opportunity to regain market share in the U.S. in this segment," said Roger Boissonneault, President and CEO of Warner Chilcott.

The Company anticipates the commercial launch of ATELVIA in early 2011.

About ATELVIAATELVIA is a bisphosphonate in a delayed-release formulation and is indicated for treatment of postmenopausal osteoporosis.  For information on dosage and administration, contraindications, warnings and precautions, adverse reactions, and other important safety and other prescribing information, please see http://www.wcrx.com/pdfs/pi/pi_atelvia.pdf.

About Warner Chilcott Warner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets.  The Company is fully integrated with internal resources dedicated to the development, manufacturing and promotion of its products.  WCRX-G.

Forward Looking Statements This press release contains forward-looking statements concerning our operations, our anticipated financial performance and financial condition, and our business plans and growth strategy and product development efforts.  These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  The words "may," "might," "will," "should," "estimate," "proj
'/>"/>

SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
2. Dr. Mahdi B. Fawzi Joins Warner Chilcott as President, Global Research and Development
3. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
4. Warner Chilcott Announces 2010 Financial Guidance Conference Call
5. Warner Chilcott Announces Secondary Equity Offering
6. Warner Chilcott Announces Early Tender Results and Receipt of Consents from a Majority of Holders of its 8-3/4% Senior Subordinated Notes due 2015
7. Warner Chilcott Prices Secondary Equity Offering
8. Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015
9. Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes
10. Warner Chilcott Announces Earnings Release Date and Conference Call For First Quarter 2010 Financial Results
11. Warner Chilcott to Present at the Bank of America Merrill Lynch Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... and TORONTO ... Corporation ( www.generex.com ) (OTCQB: GNBT) today ... implement a buccal cannabis co-development arrangement with ... been formalized. Generex and CannScience ... Technology Licensing Agreement.  Pursuant to the Agreement, ...
(Date:9/2/2015)... , Sept. 2, 2015  MGC Diagnostics Corporation ... a conference call to discuss its financial results for ... 2015. The call will be at 4:30 p.m. ET ... financial results for the third quarter of fiscal 2015 ... Participants can dial (877) 317-6789 or ...
(Date:9/2/2015)... EVANSTON, Ill. , Sept. 2, 2015 ... and a frenzy of health care M&A activity – ... place moderate-to-severe access restrictions on pharmaceutical sales reps. This ... who limit access has crossed the halfway point, according ... global sales and marketing firm ZS . ...
Breaking Medicine Technology:Generex Announces Formalization of Buccal Cannabis Co-Development Plan 2Generex Announces Formalization of Buccal Cannabis Co-Development Plan 3MGC Diagnostics Corporation to Report Third Quarter Fiscal 2015 Financial Results on Thursday, September 10, 2015 2Crossing the threshold: More than half of physicians restrict access to sales reps 2Crossing the threshold: More than half of physicians restrict access to sales reps 3Crossing the threshold: More than half of physicians restrict access to sales reps 4Crossing the threshold: More than half of physicians restrict access to sales reps 5
... 10 Ferring Pharmaceuticals today announced an ... portfolio with the acquisition of the global rights ... non-hormonal therapy indicated specifically for treatment of women ... will initially market LYSTEDA in the U.S., and ...
... , May 7 Young Innovations, Inc. (Nasdaq: YDNT ) today ... per share, payable June 15, 2010 to all shareholders of record on ... , The Company also ... Mr. McKey joined the Company in November 2003 . He has assumed positions ...
Cached Medicine Technology:Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 2Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 3Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 4Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 5Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Announces Election of New Officer 2
(Date:9/2/2015)... ... ... On September 9, 2015, over 27,000 people from all over the world ... date for the state of Utah. , “We are thrilled with the overwhelming response ... doTERRA CEO. “One of the most exciting elements of our convention is the opportunity ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Brain Aneurysm Awareness Month , which was established by the Foundation in ... awareness and education, and helping fund more research remains our top priority,” commented ...
(Date:9/2/2015)... ... ... Mobile working is increasingly more important, as business professionals are looking to be ... being launched, and mobile device usage as a whole is something people around the ... lives. What's more people are expecting mobile versions of their favorite software. , While ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is National Prostate ... that affects more than 233,000 men each year in the United States. , Prostate ... common non-skin cancer in America, affecting 1 in 7 men. One new case occurs ...
(Date:9/1/2015)... Los Angeles, CA (PRWEB) , ... September 01, 2015 , ... ... the American Medical Association, individuals with type 2 diabetes that participated in a three ... of diabetes three years down the line if they elected weight loss surgery at ...
Breaking Medicine News(10 mins):Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:New Mobility Experience From Winscribe 2Health News:New Mobility Experience From Winscribe 3Health News:September is Prostate Cancer Awareness Month 2Health News:September is Prostate Cancer Awareness Month 3Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2
... cells continue to flow to newborn in minutes after birth, ... women may want to consider asking their doctors to hold ... after the baby is born, a new study suggests. , ... the blood flow from mom to baby. While not necessarily ...
... experts say , WEDNESDAY, May 26 (HealthDay News) -- Malignant ... tens of thousands of genetic mutations which, together, contribute to ... lung tumor from a heavy smoker revealed 50,000 mutations, according ... Nature . , "People in the field have always known ...
... Complete Genomics Inc., a third-generation human genome sequencing company, ... of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), ... sequence and compare a patient,s primary lung tumor and ... to compare the patient,s genome before and after it ...
... treatment of anaplastic thyroid carcinoma has dramatically increased survival in ... say physicians at Mayo Clinic. Their findings will be presented ... Clinical Oncology , to be held June 4-8 in Chicago. ... to aggressively treat metastasis even when this rare cancer seems ...
... ... first Community of Respect™ Medical Center in the Anti-Defamation League’s (ADL’s) Southwest Region. ... ... the first Community of Respect™ Medical Center in the Anti-Defamation League’s (ADL’s) Southwest ...
... ... up to $100,000 per-violation penalties , ... Alexandria, VA (Vocus) May 26, 2010 -- More than ten major ... Network (CEN) offered by the National Association of Chain Drug Stores (NACDS) and RollStream. ...
Cached Medicine News:Health News:Waiting to Clamp the Umbilical Cord May Be Better for Babies 2Health News:Waiting to Clamp the Umbilical Cord May Be Better for Babies 3Health News:Single Lung Tumor Contains 50,000 Mutations 2Health News:Genentech uses Complete Genomics' human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature 2Health News:New treatment approach to rare cancer results in prolonged survival 2Health News:Houston Northwest Medical Center Becomes First Hospital in the Southwest Region Designated a Community of Respect™ Partner 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 3
... protein 4 (IGFBP-4) is a 24 kDa protein ... IGF-I and IGF-II. It is also present in ... 28 kDa. IGFBP-4 has been identified in all ... types, including fibroblasts, neuroblastoma, prostate and bone cells ...
... the adrenal gland and gonads, is the ... both of which may be subsequently converted ... activity, estimated at ~(less than or equal ... androstenedione levels often exceed testosterone in both ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
... a 7.5 kDa peptide which is secreted primarily ... mitogenic and metabolic actions involved in cellular growth. ... to target cell receptors. IGF-II binds with high ... monomeric protein which also serves as the receptor ...
Medicine Products: